Álvaro Martínez-Doménech

Álvaro Martínez-Doménech

Auto-generated profile, based on publicly available information

Álvaro Martínez-Doménech

Consorcio Hospital General Universitario, Dermatology Valencia Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Actas Dermo-Sifiliograficas
Verified
Journal Article
Open access
JMJ. Magdaleno-Tapial
J. Magdaleno-Tapial
PHP. Hernández-Bel
P. Hernández-Bel
CVC. Valenzuela-Oñate
C. Valenzuela-Oñate
JOJ.M. Ortiz-Salvador
J.M. Ortiz-Salvador
MGM. García-Legaz-Martínez
M. García-Legaz-Martínez
APA. Pérez-Ferriols
A. Pérez-Ferriols
The epidemiology of genital herpes has changed in recent years with an increase in the incidence of herpes simplex virus type 1 (HSV-1) infection. The aim of this study was to analyze the clinical and epidemiological characteristics of patients diagnosed with genital herpes. A retrospective observational study was designed. All patients diagnosed with genital herpes between January 2016 and January 2019 in a Sexually Transmitted Infections Unit (ITS) in Valencia, Spain, were included. We identified 895 STI diagnoses. Of these, 126 (14%) were genital herpes; 68 (54%) of these cases were in women and 58 (46%) in men. Diagnosis was confirmed by molecular detection of HSV DNA in 110 cases (87.3%). Of these, 52 were cases of HSV-1 infection (47.3%) and 58 were HSV-2 infection (52.7%). HSV-2 was more common in men (69.5%), while HSV-1 was more common in women (59.3%). In the subgroup of women, mean age at diagnosis was 26 years for HSV-1 and 34 years for HSV-2 (P=.015). Recurrent genital herpes rates were 13% for HSV-1 and 40% for HSV-2. There has been an increase in the number of cases of genital herpes caused by HSV-1 in our setting, with young women in particular being affected. This has important prognostic implications because genital herpes caused by HSV-1 is less likely to recur.

24 November 2021 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
EAElena del Alcázar
Elena del Alcázar
ALAnna López López-Ferrer
Anna López López-Ferrer
ÁMÁlvaro Martínez‐Doménech
Álvaro Martínez‐Doménech
Ricardo Ruiz-VillaverdeRicardo Ruiz-Villaverde
Ricardo Ruiz-Villaverde
MLMar Llamas-Velasco
Mar Llamas-Velasco
José Manuel CarrascosaJosé Manuel Carrascosa
José Manuel Carrascosa
Background Data on the effectiveness and safety of a drug in real-world clinical practice complement the evidence from clinical trials, which are carried out in a different setting. Little has been published on the effectiveness and safety of guselkumab in the treatment of psoriasis in clinical practice. Objectives To assess the effectiveness and safety of guselkumab at 24 weeks in patients with moderate to severe plaque psoriasis in routine clinical practice. Methods Retrospective, multicentre study of adult patients with moderate to severe plaque psoriasis treated with guselkumab for at least 24 weeks in Spain. Results We studied 343 patients, 249 of whom were followed for 24 weeks. By week 24, the mean (SD) Psoriasis Area and Severity Index (PASI) had decreased from 11.1 (7.3) to 1.7 (2.8) (-9.3; [-10.2;-8.4]), 85.9% of the patients had achieved PASI score of 4 or less and 77.9% a PASI score of 2 or less. In terms of relative PASI response, 59.4% of the patients achieved a PASI-90 response and 49.0% a PASI-100 response. On multivariate analysis, 2 factors reduced the probability of a PASI of 2 or less at 24 weeks: a BMI ≥30 (OR, 0.44; 95% CI, 0.22-0.88) and a greater previous exposure to biologic therapy (OR, 0.69; 95% CI, 0.56-0.84]). Adverse events were rare (9.9%) and led to withdrawal from treatment in only 9 patients (2.6%) by the end of the follow-up period. Conclusion The results of this study confirm the high efficacy and safety of guselkumab indicated by the clinical trial data. In clinical practice, the absolute PASI score appears to be a better marker of response to treatment than the relative value.

15 November 2019 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
JMJorge Magdaleno‐Tapial
Jorge Magdaleno‐Tapial
CVCristian Alejandro Valenzuela‐Oñate
Cristian Alejandro Valenzuela‐Oñate
JOJosé María Ortiz‐Salvador
José María Ortiz‐Salvador
ÁMÁlvaro Martínez‐Doménech
Álvaro Martínez‐Doménech
MGMarta García‐Legaz‐Martínez
Marta García‐Legaz‐Martínez
APAmparo Pérez‐Ferriols
Amparo Pérez‐Ferriols

13 September 2019 in Contact Dermatitis
Verified
Journal Article
Closed access
PDF file
JMJorge Magdaleno‐Tapial
Jorge Magdaleno‐Tapial
CVCristian Valenzuela‐Oñate
Cristian Valenzuela‐Oñate
JOJosé M. Ortiz‐Salvador
José M. Ortiz‐Salvador
MGMarta García‐Legaz‐Martínez
Marta García‐Legaz‐Martínez
ÁMÁlvaro Martínez‐Domenech
Álvaro Martínez‐Domenech
VZVioleta Zaragoza‐Ninet
Violeta Zaragoza‐Ninet

25 November 2019 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
JMJorge Magdaleno‐Tapial
Jorge Magdaleno‐Tapial
CVCristian Alejandro Valenzuela‐Oñate
Cristian Alejandro Valenzuela‐Oñate
MGMarta García‐Legaz‐Martínez
Marta García‐Legaz‐Martínez
ÁMÁlvaro Martínez‐Domenech
Álvaro Martínez‐Domenech
APAmparo Pérez‐Ferriols
Amparo Pérez‐Ferriols

1 January 2019 in Actas Dermo-Sifiliograficas
Verified
Journal Article
Closed access
JMJ. Magdaleno-Tapial
J. Magdaleno-Tapial
CVC. Valenzuela-Oñate
C. Valenzuela-Oñate
MWM.M. Giacaman-Von der Weth
M.M. Giacaman-Von der Weth
BFB. Ferrer-Guillén
B. Ferrer-Guillén
ÁMÁ. Martínez-Domenech
Á. Martínez-Domenech
PHP. Hernández-Bel
P. Hernández-Bel